HC Wainwright Issues Positive Estimate for Lipocine Earnings

Lipocine Inc. (NASDAQ:LPCN) – Stock analysts at HC Wainwright upped their Q3 2026 EPS estimates for shares of Lipocine in a research note issued to investors on Monday, September 21st. HC Wainwright analyst Y. Chen now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.39) for the quarter, up from their prior forecast of ($0.47). HC Wainwright currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Lipocine’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Lipocine’s Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.54) EPS.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million.

A number of other brokerages have also weighed in on LPCN. Cantor Fitzgerald reiterated an “overweight” rating on shares of Lipocine in a research note on Tuesday. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Finally, Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Lipocine Trading Down 3.6%

Shares of LPCN stock opened at $2.16 on Wednesday. Lipocine has a 12-month low of $1.81 and a 12-month high of $12.37. The firm’s 50 day moving average is $2.18 and its 200 day moving average is $3.03. The stock has a market capitalization of $17.80 million, a P/E ratio of -1.21 and a beta of 0.47.

Institutional Investors Weigh In On Lipocine

Hedge funds and other institutional investors have recently modified their holdings of the stock. Eversept Partners LP bought a new position in Lipocine in the 1st quarter worth $2,357,000. AIGH Capital Management LLC bought a new stake in Lipocine during the first quarter valued at about $1,598,000. Stempoint Capital LP purchased a new stake in Lipocine in the first quarter worth about $1,282,000. Seven Fleet Capital Management LP bought a new position in shares of Lipocine in the first quarter worth about $998,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Lipocine in the fourth quarter worth about $567,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.